11 completed. 11 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
| Phase 3 | 1 | Completed 1 |
Follow Blepharitis: new trials by email Literature Review of Blepharitis trials Research Report on Blepharitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis. APT-001 topical ophthalmic ointment (spinosad), Vehicle control for APT-001 topical ophthalmic ointment - Blepharitis | Phase 2 | Completed | Aperta Biosciences, LLC | 66 | 2025-11-01 | 2026-10-27 |
| Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD TP-03, TP-03 Vehicle - Meibomian Gland Dysfunction, Blepharitis | Phase 2 | Completed | Tarsus Pharmaceuticals, Inc. | 39 | 2022-08-03 | 2025-10-01 |
| Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis NCX 4251, Placebo - Blepharitis | Phase 2 | Completed | Nicox Ophthalmics, Inc. | 224 | 2020-12-14 | 2023-06-18 |
| Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis TP-03, 0.25%, TP-03 Vehicle - Blepharitis | Phase 2 / Phase 3 | Completed | Tarsus Pharmaceuticals, Inc. | 421 | 2020-09-09 | 2023-12-21 |
| Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis Fluticasone Propionate, Placebo - Blepharitis | Phase 2 | Completed | Nicox Ophthalmics, Inc. | 36 | 2019-03-18 | 2023-06-18 |
| Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease KPI-121, Vehicle - Blepharitis | Phase 2 | Completed | Kala Pharmaceuticals, Inc. | 206 | 2014-07-01 | 2021-01-11 |
| Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis Azithromycin, Povidone - Blepharitis | Phase 2 | Completed | Laboratoires Thea | 93 | 2010-03-01 | 2014-11-04 |
| The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) Azithromycin ophthalmic solution, 1%, Placebo - Blepharitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 314 | 2009-05-01 | 2013-11-21 |
| The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period Azithromycin ophthalmic solution, 1%, Placebo - Blepharitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 313 | 2009-04-01 | 2011-09-26 |
| Tea Tree Oil in the Treatment of Chronic Blepharitis Tea Tree Oil - Blepharitis | Phase 2 | Completed | Federal University of São Paulo | 34 | 2009-04-01 | 2010-02-23 |
| Treatment of Patients With Blepharitis and Facial Rosacea COL-101 (doxycycline, USP) capsules, placebo - Blepharitis, Meibomianitis | Phase 2 | Completed | Galderma R&D | 70 | 2007-11-01 | 2021-02-18 |
Meibomian Gland Dysfunction (2) · Dry Eye Syndromes (1) · Meibomitis (1) · Pain (1)
Eye Diseases (11) · Eyelid Diseases (11) · Lacrimal Apparatus Diseases (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Azithromycin (1) · Capsules (1) · Doxycycline (1) · Fluticasone (1) · Loteprednol Etabonate (1) · Povidone (1) · Tea Tree Oil (1) · spinosad (1)
Merck Sharp & Dohme LLC (2) · Nicox Ophthalmics, Inc. (2) · Tarsus Pharmaceuticals, Inc. (2) · Aperta Biosciences, LLC (1) · Federal University of São Paulo (1) · Galderma R&D (1) · Kala Pharmaceuticals, Inc. (1) · Laboratoires Thea (1)
United States (8) · Brazil (1) · France (1) · Guatemala (1)
Nicox Ophthalmics (2) · Damien Goldberg, MD (1) · David Wirta, MD (1) · Jodi Luchs, MD (1) · John Sheppard, MD (1) · Joseph Tauber, MD (1) · Josue Moran, Ph.D. (1) · Kelly Nichols, OD, PhD (1) · Kenneth Sall, MD (1) · Marc Abrams, MD (1) · Michael Graeber, MD (1) · Mitchell Shultz, MD (1) · Nahin Geha (1) · Reza Haque, MD, PhD (1)
2009 (1)